Business Context and Reporting Period
Company: NeOnc Technologies Holdings, Inc. (NTHI)
Filing Type: Form 8-K (Current Report)
Date of Report: August 12, 2026
Reporting Period: Single event date (August 12, 2026)
Business Context: The Company is an emerging growth company incorporated in Delaware, trading on The Nasdaq Stock Market LLC. This filing serves as a Regulation FD disclosure regarding the announcement of clinical trial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a current report focused on a specific corporate event (clinical data release) rather than a periodic financial report (10-K or 10-Q) containing audited or unaudited financial statements.
Material Changes
Clinical Development Update: On August 12, 2026, the Company announced results from the Phase 2a portion of the NEO100-01 clinical trial. This represents a material development in the Company's product pipeline. No financial material changes were reported in this specific document.
Guidance, Outlook, and Management Commentary
- Management Action: The Company issued a press release (Exhibit 99.1) and hosted an investor conference call to discuss the Phase 2a data.
- Investor Materials: An investor presentation (Exhibit 99.2) was furnished to accompany the conference call.
- Legal Disclaimer: The information contained in the press release and investor presentation is furnished, not filed, and is not subject to Section 18 liabilities of the Exchange Act unless expressly incorporated by reference.
- Guidance: The filing text does not provide specific forward-looking financial guidance or updated operational outlook beyond the discussion of the clinical data.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific efficacy and safety data from the Phase 2a portion of the NEO100-01 trial.
- Examine Exhibit 99.2 (Investor Presentation) for management's interpretation of the data and potential next steps for the trial.
- Verify the Company's cash runway and liquidity status in the most recent 10-Q or 10-K, as this 8-K does not contain financial position data.
- Confirm the regulatory status of the NEO100-01 program and any planned Phase 2b or Phase 3 timelines mentioned in the conference call.